streptococcus pneumoniae atcc 49612 Search Results


caption a7 isolate mpc auc mpc  (ATCC)
92
ATCC caption a7 isolate mpc auc mpc
Derivation of pharmacokinetics of <t> MPC-targeted </t> models
Caption A7 Isolate Mpc Auc Mpc, supplied by ATCC, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/streptococcus+pneumoniae+atcc+49612/Enterococcus+hirae+Farrow+and+Collins/pmc00166082-199-18-64
Average 92 stars, based on 1 article reviews
caption a7 isolate mpc auc mpc - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier
streptococcus pneumoniae atcc 49612  (ATCC)
96
ATCC streptococcus pneumoniae atcc 49612
Derivation of pharmacokinetics of <t> MPC-targeted </t> models
Streptococcus Pneumoniae Atcc 49612, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/streptococcus+pneumoniae+atcc+49612/Streptococcus+pneumoniae/pm20502080-55-0-2
Average 96 stars, based on 1 article reviews
streptococcus pneumoniae atcc 49612 - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
enterococcus hirae  (ATCC)
96
ATCC enterococcus hirae
Derivation of pharmacokinetics of <t> MPC-targeted </t> models
Enterococcus Hirae, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/streptococcus+pneumoniae+atcc+49612/Enterococcus+hirae/pmc00303306-30-8-23
Average 96 stars, based on 1 article reviews
enterococcus hirae - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
cs-49612  (ChemBo Pharma Co Ltd)
90
ChemBo Pharma Co Ltd cs-49612
Derivation of pharmacokinetics of <t> MPC-targeted </t> models
Cs 49612, supplied by ChemBo Pharma Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/streptococcus+pneumoniae+atcc+49612/cs+49612/pmc07145267-137-6-15
Average 90 stars, based on 1 article reviews
cs-49612 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


Derivation of pharmacokinetics of MPC-targeted models

Journal:

Article Title: Activities of Mutant Prevention Concentration-Targeted Moxifloxacin and Levofloxacin against Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model

doi: 10.1128/AAC.47.8.2606-2614.2003

Figure Lengend Snippet: Derivation of pharmacokinetics of MPC-targeted models

Article Snippet: MPC-targeted moxifloxacin models were designed in the same manner (Table ). table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Isolate MPC AUC/MPC Adjusted t 1/2 (h) Adjusted peak a (μg/ml) Adjusted peak b (μg/ml) Dose c MXF d LEV e MXF LEV MXF LEV MXF LEV MXF LEV MXF LEV 79 0.5 4 96 12 6 12 0.75 29.5 0.375 20.36 66.7 2,458.3 ATCC 49619 0.5 2 96 24 6 12 1.5 14.5 0.75 10.01 133.3 1,208.3 KD2138 8 64 6 0.75 6 12 0.75 29.5 0.375 20.36 66.7 2,458.3 KD2139 4 32 12 1.5 6 12 0.75 29.5 0.375 20.36 66.7 2,458.3 Open in a separate window a Adjusted total (non-protein-bound) peak concentration. b Adjusted peak (free concentration) after protein binding (moxifloxacin, 50%; levifloxacin, 31%) of each fluoroquinolone considered. c Dose (in milligrams) corresponding to adjusted total (non-protein-bound) peak concentration (usual therapeutic doses for moxifloxacin, 400 mg; and for levofloxacin, 500 mg). d MXF, moxifloxacin. e LEV, levofloxacin.

Techniques:

IVPM pharmacokinetics and pharmacodynamics

Journal:

Article Title: Activities of Mutant Prevention Concentration-Targeted Moxifloxacin and Levofloxacin against Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model

doi: 10.1128/AAC.47.8.2606-2614.2003

Figure Lengend Snippet: IVPM pharmacokinetics and pharmacodynamics

Article Snippet: MPC-targeted moxifloxacin models were designed in the same manner (Table ). table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Isolate MPC AUC/MPC Adjusted t 1/2 (h) Adjusted peak a (μg/ml) Adjusted peak b (μg/ml) Dose c MXF d LEV e MXF LEV MXF LEV MXF LEV MXF LEV MXF LEV 79 0.5 4 96 12 6 12 0.75 29.5 0.375 20.36 66.7 2,458.3 ATCC 49619 0.5 2 96 24 6 12 1.5 14.5 0.75 10.01 133.3 1,208.3 KD2138 8 64 6 0.75 6 12 0.75 29.5 0.375 20.36 66.7 2,458.3 KD2139 4 32 12 1.5 6 12 0.75 29.5 0.375 20.36 66.7 2,458.3 Open in a separate window a Adjusted total (non-protein-bound) peak concentration. b Adjusted peak (free concentration) after protein binding (moxifloxacin, 50%; levifloxacin, 31%) of each fluoroquinolone considered. c Dose (in milligrams) corresponding to adjusted total (non-protein-bound) peak concentration (usual therapeutic doses for moxifloxacin, 400 mg; and for levofloxacin, 500 mg). d MXF, moxifloxacin. e LEV, levofloxacin.

Techniques: